Immune signatures of treatment resistant schizophrenia: a FACE-SZ study Running title: Immune profile of treatment-resistant schizophrenia - Neuropsychiatrie- Recherche épidémiologique et clinique (U1061) Accéder directement au contenu
Article Dans Une Revue Schizophrenia Bulletin Open Année : 2021

Immune signatures of treatment resistant schizophrenia: a FACE-SZ study Running title: Immune profile of treatment-resistant schizophrenia

Emilie Terro
  • Fonction : Auteur
Wahid Boukouaci
  • Fonction : Auteur
Ching-Lieng Lu
  • Fonction : Auteur
Fabrice Berna
  • Fonction : Auteur
Caroline Barau
  • Fonction : Auteur
Delphine Capdevielle
  • Fonction : Auteur
Julie Clauss-Kobayashi
  • Fonction : Auteur
Isabelle Chereau
  • Fonction : Auteur
Thierry d'Amato
  • Fonction : Auteur
Caroline Dubertret
  • Fonction : Auteur
Julien Dubreucq
Guillaume Fond
Hakim Laouamri
  • Fonction : Auteur
Sylvain Leignier
  • Fonction : Auteur
Christophe Lancon
  • Fonction : Auteur
Pierre-Michel Llorca
Jasmina Mallet
Philippe Le Corvoisier
Christine Passerieux
  • Fonction : Auteur
S. Parola
  • Fonction : Auteur
Baptiste Pignon
Mathieu Urbach
  • Fonction : Auteur
Andrei Szoke
  • Fonction : Auteur
Ryad Tamouza
Franck Schürhoff

Résumé

Abstract Treatment-resistant schizophrenia (TRS) affects around 30% of patients with schizophrenia (SZ) resulting in poor functioning, relapses, and reduced quality of life. Convergent findings show that inflammation could contribute to resistance. We thus search for immune signatures of patients with TRS/ultra TRS (UTRS) in a sample of community-dwelling outpatients with SZ. In total, 195 stabilized SZ patients (mean age = 31.2 years, 73% male gender) were consecutively included in the network of the FondaMental Expert Centers for Schizophrenia in France and received a thorough clinical assessment. At inclusion, psychotic symptomatology was evaluated by the Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Circulating serum/plasma levels of a large panel of markers reflecting the main inflammatory pathways were evaluated. TRS was defined by current treatment by clozapine (CLZ) and UTRS by current CLZ treatment + PANSS total score ≥ 70. The frequency of TRS and UTRS patients was, respectively, 20% and 7.7% and was defined using multivariable analysis elevated by high levels of interleukin (IL)-12/IL-23p40, IL-17A, IL-10, and beta 2 microglobulin (B2M) and IL-12/IL-23p40, IL-17A, IL-6, IL-10, IFNγ, and B2M, respectively. These observations suggest that resistance and ultra resistance to CLZ treatment are underpinned by pro-inflammatory molecules mainly belonging to the T helper 17 pathway, a finding making sense given the interplay between inflammation and antipsychotic treatment responses. If confirmed, our findings may allow us to consider IL-23/IL-17 pathway as a therapeutic target for patients with resistance to antipsychotics.
Fichier principal
Vignette du fichier
TRS_Inflammation_Article_acceptedversion.pdf (278.37 Ko) Télécharger le fichier
2021 Leboyer Immune signatures of treatment resistant schizophrenia- a FACE-SZ study.pdf (998.7 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03347951 , version 1 (27-01-2023)

Identifiants

Citer

Marion Leboyer, Ophélia Godin, Emilie Terro, Wahid Boukouaci, Ching-Lieng Lu, et al.. Immune signatures of treatment resistant schizophrenia: a FACE-SZ study Running title: Immune profile of treatment-resistant schizophrenia. Schizophrenia Bulletin Open, 2021, 2 (1), pp.sgab012. ⟨10.1093/schizbullopen/sgab012⟩. ⟨hal-03347951⟩
23 Consultations
25 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More